Immunocore to present at the 2024 Cantor Global Healthcare Conference
13 9월 2024 - 5:05AM
Immunocore to present at the 2024 Cantor Global
Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings
plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a
commercial-stage biotechnology company pioneering and delivering
transformative immunomodulating medicines to radically improve
outcomes for patients with cancer, infectious diseases and
autoimmune diseases, today announced that management will
participate in the 2024 Cantor Global Healthcare Conference.
2024
Cantor Global Healthcare
Conference Fireside
Chat: Thursday, September 19, 2024, at 12:45 p.m. EDT
The presentation will be webcast live and can be
accessed by visiting ‘Events & Presentations’, under ‘Events’,
via the ‘Investors’ section of Immunocore’s website at
www.immunocore.com. Following the event, a replay of the
presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of CommunicationsT: +44
(0) 7458030732E: sebastien.desprez@immunocore.comFollow on Twitter:
@Immunocore
Investor Relations
Clayton Robertson, Head of Investor RelationsT:
+1 (215) 384-4781E: ir@immunocore.com
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
